Search PubMed⌕ Search

Biomedical subjects

G Ambrosini

Publications and source records attributed to G Ambrosini.

66 records · Page 4Linked to original sources
PubMed1991

Longterm treatment of rheumatoid arthritis with OM-8980. A retrospective study.

OM-8980 is an immunomodulating drug which has been shown in double blind placebo controlled trials to be effective in the management of rheumatoid arthritis (RA). For this report, longterm information was collected from 32 patients (27 women, 5 men) with RA who had been treated for periods ranging from one to over 8 years with OM-8980 daily (median 5 years). Statistically significant reductions were observed in duration of morning stiffness, articular index, pain and erythrocyte sedimentation rate (ESR). An improvement or strong improvement in overall condition was noted in 23 patients. Adverse events were reported in only 3 patients and were minimal in nature. Our study demonstrates that OM-8980 is an effective longterm slow acting antirheumatic drug which has minimal adverse effects and should be considered to have a role to play in the management of RA.

Adjuvants, Immunologic↗
PubMed1991

The management of cervical carcinoma in the Gynaecologic and Obstetric Institute of Sassari in ten-year period 1980-89.

We have considered 91 cases of uterine cervical carcinoma observed in the period 1980-89, of which 31 (34%) at stage 0, and 23 (25.2%) at stage IB. The operative index was of 85.7%. Of 78 cases operated, 22 (28.2%) were treated with post-surgical adjuvant radiotherapy because of the presence of risk factors. The relapse incidence (follow-up 8-118 months) was in total 14.6% (12 relapses) with an NED-survival of 79.1% (at the first stage B 4.3% of relapses with an NED-survival of 95.6%). We have emphasized the importance of adjuvant radiotherapy which has allowed the progressive improvement in the therapeutic results of the last years.

Adult↗
PubMed1988

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.

From February 1983 to January 1985, 497 patients with advanced breast cancer were randomly allocated to receive either epirubicin or doxorubicin in the following combination chemotherapy regimen: fluorouracil (5-FU) 500 mg/m2 intravenous (IV) on days 1 and 8; epirubicin or doxorubicin 50 mg/m2 IV on day 1; cyclophosphamide 500 mg/m2 IV on day 1 (FEC or FAC). Cycles were repeated every 21 days until progression or to cumulative doses of 700 mg/m2 for epirubicin and 550 mg/m2 for doxorubicin. Dose reductions were applied according to the standard criteria. Activity was evaluated in 443 patients (222 in the FEC arm and 221 in the FAC arm). The two experimental groups were comparable in age, performance status, menopausal status, histology, previous treatments, and site of the disease. The overall response rate (complete response and partial response [CR + PR]) was not significantly different: 53.6% for FEC and 56.5% for FAC. The median time to progression was 273 days for FEC and 314 days for FAC; the median survival time was 591 and 613 days, respectively. Leukopenia, anemia, nausea, and vomiting were significantly lower in patients treated with FEC. As for cardiotoxicity, four cases of congestive heart failure (CHF) were recorded among patients treated with FAC while only one was observed in the FEC group. These results indicate that epirubicin in a combination chemotherapy regimen is as active as doxorubicin and is significantly less toxic.

Adult↗
PubMed1986

Neoadjuvant chemotherapy with vincristine, bleomycin and methotrexate combined with radiotherapy in advanced head and neck squamous cell carcinoma.

From September 1980 to August 1981, 25 patients with advanced head and neck squamous cell carcinoma were treated at the Centro Oncologico, Trento, by a chemo-radiotherapeutic combination. The treatment protocol consisted of 4-6 courses of VBM (vincristine, bleomycin and methotrexate) followed by conventional radiotherapy (65 Gy). Only to VBM responders (15 patients) were administered 10 cycles of vincristine-methotrexate. At the end of induction chemotherapy an overall response of 60% (12% complete, 48% partial) was obtained. At the end of radiotherapy the responses were 52.5% complete and 35.5% partial, for an overall response of 88%. The overall survival at 60 months was 8%. This combined approach, in spite of the satisfactory immediate local response rate, does not offer advantages for survival in comparison to conventional treatment modalities.

Adult↗
PubMed1980

[Burkitt's lymphoma with leukemic evolution].

An account of the clinical, histopathological and aetiopathogenetic aspects of Burkitt's lymphoma is followed by the presentation of a personal case, in which the typical clinical picture of the African form progressed to terminal leukaemia. The aetiological and pathogenetic rôle of the Epstein-Barr virus is also briefly discussed.

Burkitt Lymphoma↗
PubMedDate not supplied

Use of 5-fluorouracil, epirubicin and mitomycin C (FEM) as adjuvant therapy in node-positive, radically-resected gastric cancer patients: survey of a general hospital experience.

Between 1/1986 and 6/1996, 37 consecutive patients affected by node-positive gastric cancer (GC) were treated with radical surgery and received 5-fluorouracil, epirubicin and mitomycin C (FEM) as adjuvant treatment. Only 57% of the patients received all six cycles and the reasons for treatment withdrawal were mainly related to concomitant pathologies and prolonged leukopenia. After a median follow-up of 39 months, the 3-year disease-free survival, disease-related survival and overall survival were 75.8%, 83.7% and 78.6% respectively. A statistically significant difference in survival was found in the subgroup of patients receiving more than three courses of treatment.

Adult↗